Latest news
Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingViewTradingView · Thu, 06 Aug 2026 20:35:29 GMTLYEL: Net loss rose to $44.8M as R&D spending increased; pivotal CAR T-cell trial data expected in 2026–2027 - TradingViewTradingView · Thu, 06 Aug 2026 20:31:05 GMTLYEL: Advanced pivotal trials and strong cash reserves position the company for key milestones ahead - TradingViewTradingView · Thu, 06 Aug 2026 20:28:56 GMTLYEL Q2'26 Earnings: revenue estimate is 4.60K USD - TradingViewTradingView · Wed, 05 Aug 2026 11:00:15 GMTPrice to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL - TradingViewTradingView · Wed, 29 Jul 2026 06:51:09 GMT